WA
RPRX icon

Waddell & Associates’s Royalty Pharma RPRX Stock Holding History

Waddell & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
5,486
+1,212
+28% +$63.1K 0.02% 396
2026
Q1 		$205K Buy
+4,274
New +$187K 0.01% 417

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Waddell & Associates's RPRX Position: Q2 2026 in Review

Waddell & Associates increased its Royalty Pharma (RPRX) stake by 28% in Q2 2026, buying an estimated $63.1K and bringing the position to 5,486 shares worth $308K. The position accounts for 0.02% of the portfolio, ranked #396.

Waddell & Associates first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Waddell & Associates held 5,486 shares of Royalty Pharma worth $308K as of Q2 2026.
  • Waddell & Associates bought 1,212 Royalty Pharma shares in Q2 2026, an estimated $63.1K.
  • Royalty Pharma made up 0.02% of Waddell & Associates's portfolio in Q2 2026, its #396 holding.
  • Waddell & Associates first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.